Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- FDA Presents Compliance Guide for Structure/Function Claims
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Dietary Supplement a Potential Treatment for Canavan Disease
Research suggests that supplementation with N-acetylaspartic acid (NAA)-derived acetate would increase synthesis of myelin-related fatty acids and lipids and could be potential therapy for Canavan disease.
- Dietary Supplement a Potential Treatment for Canavan Disease
Research suggests that supplementation with N-acetylaspartic acid (NAA)-derived acetate would increase synthesis of myelin-related fatty acids and lipids and could be potential therapy for Canavan disease.
- Dietary Supplement a Potential Treatment for Canavan Disease
Research suggests that supplementation with N-acetylaspartic acid (NAA)-derived acetate would increase synthesis of myelin-related fatty acids and lipids and could be potential therapy for Canavan disease.
- Dietary Supplement a Potential Treatment for Canavan Disease
Research suggests that supplementation with N-acetylaspartic acid (NAA)-derived acetate would increase synthesis of myelin-related fatty acids and lipids and could be potential therapy for Canavan disease.
- Beneo(TM) Synergy 1 Protects Seniors’ Health
Results of the new study demonstrate that Beneo(TM) Synergy 1, combined with probiotics like the active cultures in yogurt, help reverse such digestive ‘aging,’ to the improvement of intestinal function and well being.
- Beneo(TM) Synergy 1 Protects Seniors’ Health
Results of the new study demonstrate that Beneo(TM) Synergy 1, combined with probiotics like the active cultures in yogurt, help reverse such digestive ‘aging,’ to the improvement of intestinal function and well being.
- Beneo(TM) Synergy 1 Protects Seniors’ Health
Results of the new study demonstrate that Beneo(TM) Synergy 1, combined with probiotics like the active cultures in yogurt, help reverse such digestive ‘aging,’ to the improvement of intestinal function and well being.
- Beneo(TM) Synergy 1 Protects Seniors’ Health
Results of the new study demonstrate that Beneo(TM) Synergy 1, combined with probiotics like the active cultures in yogurt, help reverse such digestive ‘aging,’ to the improvement of intestinal function and well being.
- Beneo(TM) Synergy 1 Protects Seniors’ Health
Results of the new study demonstrate that Beneo(TM) Synergy 1, combined with probiotics like the active cultures in yogurt, help reverse such digestive ‘aging,’ to the improvement of intestinal function and well being.
- Beneo(TM) Synergy 1 Protects Seniors’ Health
Results of the new study demonstrate that Beneo(TM) Synergy 1, combined with probiotics like the active cultures in yogurt, help reverse such digestive ‘aging,’ to the improvement of intestinal function and well being.
- Raftilose® Synergy 1 Shown to Protect Against Colon Cancer
An EU-funded project designed to evaluate whether synbiotics can reduce the risk of colorectal cancer has found that Raftilose®Synergy1 combined with probiotics does have a positive effect; results of the research show that by taking a synbiotic each day, the damage to cell DNA can be significantly reduced.
- Raftilose® Synergy 1 Shown to Protect Against Colon Cancer
An EU-funded project designed to evaluate whether synbiotics can reduce the risk of colorectal cancer has found that Raftilose®Synergy1 combined with probiotics does have a positive effect; results of the research show that by taking a synbiotic each day, the damage to cell DNA can be significantly reduced.
- Raftilose® Synergy 1 Shown to Protect Against Colon Cancer
An EU-funded project designed to evaluate whether synbiotics can reduce the risk of colorectal cancer has found that Raftilose®Synergy1 combined with probiotics does have a positive effect; results of the research show that by taking a synbiotic each day, the damage to cell DNA can be significantly reduced.
- Raftilose® Synergy 1 Shown to Protect Against Colon Cancer
An EU-funded project designed to evaluate whether synbiotics can reduce the risk of colorectal cancer has found that Raftilose®Synergy1 combined with probiotics does have a positive effect; results of the research show that by taking a synbiotic each day, the damage to cell DNA can be significantly reduced.
- Raftilose® Synergy 1 Shown to Protect Against Colon Cancer
An EU-funded project designed to evaluate whether synbiotics can reduce the risk of colorectal cancer has found that Raftilose®Synergy1 combined with probiotics does have a positive effect; results of the research show that by taking a synbiotic each day, the damage to cell DNA can be significantly reduced.
- Raftilose® Synergy 1 Shown to Protect Against Colon Cancer
An EU-funded project designed to evaluate whether synbiotics can reduce the risk of colorectal cancer has found that Raftilose®Synergy1 combined with probiotics does have a positive effect; results of the research show that by taking a synbiotic each day, the damage to cell DNA can be significantly reduced.
- Raftilose® Synergy 1 Shown to Protect Against Colon Cancer
An EU-funded project designed to evaluate whether synbiotics can reduce the risk of colorectal cancer has found that Raftilose®Synergy1 combined with probiotics does have a positive effect; results of the research show that by taking a synbiotic each day, the damage to cell DNA can be significantly reduced.
- Raftilose® Synergy 1 Shown to Protect Against Colon Cancer
An EU-funded project designed to evaluate whether synbiotics can reduce the risk of colorectal cancer has found that Raftilose®Synergy1 combined with probiotics does have a positive effect; results of the research show that by taking a synbiotic each day, the damage to cell DNA can be significantly reduced.
- Raftilose® Synergy 1 Shown to Protect Against Colon Cancer
An EU-funded project designed to evaluate whether synbiotics can reduce the risk of colorectal cancer has found that Raftilose®Synergy1 combined with probiotics does have a positive effect; results of the research show that by taking a synbiotic each day, the damage to cell DNA can be significantly reduced.
- Study Indicates That GliSODin® May Provide Significant Protection Against UV Radiation-induced Skin Changes
In double-blind, placebo controlled study, UV skin burn (actinic erythema) was induced on the inner-forearms of healthy subjects before supplementation with GliSODin or placebo, and each week for four weeks during supplementation; color of the skin was measured by chromometry, and changes in skin due to inflammation were assessed by videocapillaroscopy.
- Study Indicates That GliSODin® May Provide Significant Protection Against UV Radiation-induced Skin Changes
In double-blind, placebo controlled study, UV skin burn (actinic erythema) was induced on the inner-forearms of healthy subjects before supplementation with GliSODin or placebo, and each week for four weeks during supplementation; color of the skin was measured by chromometry, and changes in skin due to inflammation were assessed by videocapillaroscopy.
- Study Indicates That GliSODin® May Provide Significant Protection Against UV Radiation-induced Skin Changes
In double-blind, placebo controlled study, UV skin burn (actinic erythema) was induced on the inner-forearms of healthy subjects before supplementation with GliSODin or placebo, and each week for four weeks during supplementation; color of the skin was measured by chromometry, and changes in skin due to inflammation were assessed by videocapillaroscopy.
- Study Indicates That GliSODin® May Provide Significant Protection Against UV Radiation-induced Skin Changes
In double-blind, placebo controlled study, UV skin burn (actinic erythema) was induced on the inner-forearms of healthy subjects before supplementation with GliSODin or placebo, and each week for four weeks during supplementation; color of the skin was measured by chromometry, and changes in skin due to inflammation were assessed by videocapillaroscopy.
- Study on Pharmanex Tegreen 97(R) Finds Benefits in Blood Sugar Control and Weight Loss
Study recently presented at the American Heart Association's Sixth Annual Conference indicates that Tegreen 97(R) provides blood sugar control, body fat burning properties and weight-loss benefits in an experimental setting of Metabolic Syndrome X subjects.
- Study on Pharmanex Tegreen 97(R) Finds Benefits in Blood Sugar Control and Weight Loss
Study recently presented at the American Heart Association's Sixth Annual Conference indicates that Tegreen 97(R) provides blood sugar control, body fat burning properties and weight-loss benefits in an experimental setting of Metabolic Syndrome X subjects.
- Study on Pharmanex Tegreen 97(R) Finds Benefits in Blood Sugar Control and Weight Loss
Study recently presented at the American Heart Association's Sixth Annual Conference indicates that Tegreen 97(R) provides blood sugar control, body fat burning properties and weight-loss benefits in an experimental setting of Metabolic Syndrome X subjects.
- Study on Pharmanex Tegreen 97(R) Finds Benefits in Blood Sugar Control and Weight Loss
Study recently presented at the American Heart Association's Sixth Annual Conference indicates that Tegreen 97(R) provides blood sugar control, body fat burning properties and weight-loss benefits in an experimental setting of Metabolic Syndrome X subjects.
- Study on Pharmanex Tegreen 97(R) Finds Benefits in Blood Sugar Control and Weight Loss
Study recently presented at the American Heart Association's Sixth Annual Conference indicates that Tegreen 97(R) provides blood sugar control, body fat burning properties and weight-loss benefits in an experimental setting of Metabolic Syndrome X subjects.
- Study on Pharmanex Tegreen 97(R) Finds Benefits in Blood Sugar Control and Weight Loss
Study recently presented at the American Heart Association's Sixth Annual Conference indicates that Tegreen 97(R) provides blood sugar control, body fat burning properties and weight-loss benefits in an experimental setting of Metabolic Syndrome X subjects.
- Irritable Bowel Syndrome (IBS) Study - Recruiting Completed
Company announces completion of recruiting for their Irritable Bowel Syndrome (IBS) Clinical Trial utilizing ImmunoLin.
- Irritable Bowel Syndrome (IBS) Study - Recruiting Completed
Company announces completion of recruiting for their Irritable Bowel Syndrome (IBS) Clinical Trial utilizing ImmunoLin.
- Irritable Bowel Syndrome (IBS) Study - Recruiting Completed
Company announces completion of recruiting for their Irritable Bowel Syndrome (IBS) Clinical Trial utilizing ImmunoLin.
- Irritable Bowel Syndrome (IBS) Study - Recruiting Completed
Company announces completion of recruiting for their Irritable Bowel Syndrome (IBS) Clinical Trial utilizing ImmunoLin.
- Natural Extract for Treating MRSA Presented
Research on allicin presented at American Society for Microbiology meeting in Atlanta.
- Natural Extract for Treating MRSA Presented
Research on allicin presented at American Society for Microbiology meeting in Atlanta.
- Raisins As A Functional Food For Oral Health
Researchers at the University of Illinois at Chicago School of Dentistry have determined that compounds in raisins suppress bacteria that cause cavities and gum disease. According to research presented at the meeting of the American Society for Microbiology, five compounds (oleanolic acid, oleanolic aldehyde, betulin, betulinic acid and 5-(hydroxymethyl)-2-furfural) seem to make teeth and gums healthier, in the case of oleanic acid, by slowing growth of a cavity causing bacteria and inhibiting the bacteria from sticking to surfaces.
- Raisins As A Functional Food For Oral Health
Researchers at the University of Illinois at Chicago School of Dentistry have determined that compounds in raisins suppress bacteria that cause cavities and gum disease. According to research presented at the meeting of the American Society for Microbiology, five compounds (oleanolic acid, oleanolic aldehyde, betulin, betulinic acid and 5-(hydroxymethyl)-2-furfural) seem to make teeth and gums healthier, in the case of oleanic acid, by slowing growth of a cavity causing bacteria and inhibiting the bacteria from sticking to surfaces.
- Raisins As A Functional Food For Oral Health
Researchers at the University of Illinois at Chicago School of Dentistry have determined that compounds in raisins suppress bacteria that cause cavities and gum disease. According to research presented at the meeting of the American Society for Microbiology, five compounds (oleanolic acid, oleanolic aldehyde, betulin, betulinic acid and 5-(hydroxymethyl)-2-furfural) seem to make teeth and gums healthier, in the case of oleanic acid, by slowing growth of a cavity causing bacteria and inhibiting the bacteria from sticking to surfaces.
- Raisins As A Functional Food For Oral Health
Researchers at the University of Illinois at Chicago School of Dentistry have determined that compounds in raisins suppress bacteria that cause cavities and gum disease. According to research presented at the meeting of the American Society for Microbiology, five compounds (oleanolic acid, oleanolic aldehyde, betulin, betulinic acid and 5-(hydroxymethyl)-2-furfural) seem to make teeth and gums healthier, in the case of oleanic acid, by slowing growth of a cavity causing bacteria and inhibiting the bacteria from sticking to surfaces.
- New Clinical Trial Shows Diachrome Improves Diabetes Care for Patients with Poorly-Controlled Blood Sugar Levels on Prescription Medications
Results from a new clinical trial that show daily supplementation with Diachrome(R)can improve uncontrolled blood sugar levels and cardiovascular risk factors in people with type 2 diabetes on prescription medications in a managed care setting; study evaluated 369 subjects and was presented at the American Diabetes Association (ADA) 65th Annual Scientific Sessions in San Diego, CA.
- New Clinical Trial Shows Diachrome Improves Diabetes Care for Patients with Poorly-Controlled Blood Sugar Levels on Prescription Medications
Results from a new clinical trial that show daily supplementation with Diachrome(R)can improve uncontrolled blood sugar levels and cardiovascular risk factors in people with type 2 diabetes on prescription medications in a managed care setting; study evaluated 369 subjects and was presented at the American Diabetes Association (ADA) 65th Annual Scientific Sessions in San Diego, CA.
- New Clinical Trial Shows Diachrome Improves Diabetes Care for Patients with Poorly-Controlled Blood Sugar Levels on Prescription Medications
Results from a new clinical trial that show daily supplementation with Diachrome(R)can improve uncontrolled blood sugar levels and cardiovascular risk factors in people with type 2 diabetes on prescription medications in a managed care setting; study evaluated 369 subjects and was presented at the American Diabetes Association (ADA) 65th Annual Scientific Sessions in San Diego, CA.
- New Clinical Trial Shows Diachrome Improves Diabetes Care for Patients with Poorly-Controlled Blood Sugar Levels on Prescription Medications
Results from a new clinical trial that show daily supplementation with Diachrome(R)can improve uncontrolled blood sugar levels and cardiovascular risk factors in people with type 2 diabetes on prescription medications in a managed care setting; study evaluated 369 subjects and was presented at the American Diabetes Association (ADA) 65th Annual Scientific Sessions in San Diego, CA.
- New Clinical Trial Shows Diachrome Improves Diabetes Care for Patients with Poorly-Controlled Blood Sugar Levels on Prescription Medications
Results from a new clinical trial that show daily supplementation with Diachrome(R)can improve uncontrolled blood sugar levels and cardiovascular risk factors in people with type 2 diabetes on prescription medications in a managed care setting; study evaluated 369 subjects and was presented at the American Diabetes Association (ADA) 65th Annual Scientific Sessions in San Diego, CA.
- Advitech Announces Completion of 2nd Study on XP-828L For Psoriasis
multi-centre, randomized double-blind, placebo-controlled study was conducted over a 112-day period; final results to be released July 5, 2005.
- Advitech Announces Completion of 2nd Study on XP-828L For Psoriasis
multi-centre, randomized double-blind, placebo-controlled study was conducted over a 112-day period; final results to be released July 5, 2005.
- Advitech Announces Completion of 2nd Study on XP-828L For Psoriasis
multi-centre, randomized double-blind, placebo-controlled study was conducted over a 112-day period; final results to be released July 5, 2005.
- Advitech Announces Completion of 2nd Study on XP-828L For Psoriasis
multi-centre, randomized double-blind, placebo-controlled study was conducted over a 112-day period; final results to be released July 5, 2005.
- New Study Published In Leading Journal Reinforces Safety Of Chromax(R) Chromium Picolinate
Results of a new study reaffirming the safety of Chromax® chromium picolinate will be published in an upcoming issue of Mutation Research Genetic Toxicology and Environmental Mutagenesis.
- New Study Published In Leading Journal Reinforces Safety Of Chromax(R) Chromium Picolinate
Results of a new study reaffirming the safety of Chromax® chromium picolinate will be published in an upcoming issue of Mutation Research Genetic Toxicology and Environmental Mutagenesis.
- New Study Published In Leading Journal Reinforces Safety Of Chromax(R) Chromium Picolinate
Results of a new study reaffirming the safety of Chromax® chromium picolinate will be published in an upcoming issue of Mutation Research Genetic Toxicology and Environmental Mutagenesis.
- New Study Published In Leading Journal Reinforces Safety Of Chromax(R) Chromium Picolinate
Results of a new study reaffirming the safety of Chromax® chromium picolinate will be published in an upcoming issue of Mutation Research Genetic Toxicology and Environmental Mutagenesis.
- New Study Published In Leading Journal Reinforces Safety Of Chromax(R) Chromium Picolinate
Results of a new study reaffirming the safety of Chromax® chromium picolinate will be published in an upcoming issue of Mutation Research Genetic Toxicology and Environmental Mutagenesis.
- New Study Published In Leading Journal Reinforces Safety Of Chromax(R) Chromium Picolinate
Results of a new study reaffirming the safety of Chromax® chromium picolinate will be published in an upcoming issue of Mutation Research Genetic Toxicology and Environmental Mutagenesis.
- New Study Published In Leading Journal Reinforces Safety Of Chromax(R) Chromium Picolinate
Results of a new study reaffirming the safety of Chromax® chromium picolinate will be published in an upcoming issue of Mutation Research Genetic Toxicology and Environmental Mutagenesis.
- New Study Published In Leading Journal Reinforces Safety Of Chromax(R) Chromium Picolinate
Results of a new study reaffirming the safety of Chromax® chromium picolinate will be published in an upcoming issue of Mutation Research Genetic Toxicology and Environmental Mutagenesis.
- The Quigley Corporation Announces Results of Animal Model Inflammation Studies of Its QR440 Botanical, Anti-Inflammatory Compound
Company has obtained results from a series of In-Vivo (animal model) inflammation studies, finds Delayed-Type- Hypersensitivity T cell response reduced in mice, and granulyte movement to inflammation site also reduced.
- The Quigley Corporation Announces Results of Animal Model Inflammation Studies of Its QR440 Botanical, Anti-Inflammatory Compound
Company has obtained results from a series of In-Vivo (animal model) inflammation studies, finds Delayed-Type- Hypersensitivity T cell response reduced in mice, and granulyte movement to inflammation site also reduced.
- Ladislav Pataki to Head Research and Development at Ameritech International Corp.
Ladislav Pataki, PhD, CSc, ISASc has been appointed Director of Research and Development at Ameritech International Corp. Dr. Pataki developed both the PowerLean and NutrLife health and wellness lines of products recently purchased by Ameritech.
- Ladislav Pataki to Head Research and Development at Ameritech International Corp.
Ladislav Pataki, PhD, CSc, ISASc has been appointed Director of Research and Development at Ameritech International Corp. Dr. Pataki developed both the PowerLean and NutrLife health and wellness lines of products recently purchased by Ameritech.
- Ladislav Pataki to Head Research and Development at Ameritech International Corp.
Ladislav Pataki, PhD, CSc, ISASc has been appointed Director of Research and Development at Ameritech International Corp. Dr. Pataki developed both the PowerLean and NutrLife health and wellness lines of products recently purchased by Ameritech.
- Ladislav Pataki to Head Research and Development at Ameritech International Corp.
Ladislav Pataki, PhD, CSc, ISASc has been appointed Director of Research and Development at Ameritech International Corp. Dr. Pataki developed both the PowerLean and NutrLife health and wellness lines of products recently purchased by Ameritech.
- Ladislav Pataki to Head Research and Development at Ameritech International Corp.
Ladislav Pataki, PhD, CSc, ISASc has been appointed Director of Research and Development at Ameritech International Corp. Dr. Pataki developed both the PowerLean and NutrLife health and wellness lines of products recently purchased by Ameritech.
- Ladislav Pataki to Head Research and Development at Ameritech International Corp.
Ladislav Pataki, PhD, CSc, ISASc has been appointed Director of Research and Development at Ameritech International Corp. Dr. Pataki developed both the PowerLean and NutrLife health and wellness lines of products recently purchased by Ameritech.
- Ladislav Pataki to Head Research and Development at Ameritech International Corp.
Ladislav Pataki, PhD, CSc, ISASc has been appointed Director of Research and Development at Ameritech International Corp. Dr. Pataki developed both the PowerLean and NutrLife health and wellness lines of products recently purchased by Ameritech.
- Ladislav Pataki to Head Research and Development at Ameritech International Corp.
Ladislav Pataki, PhD, CSc, ISASc has been appointed Director of Research and Development at Ameritech International Corp. Dr. Pataki developed both the PowerLean and NutrLife health and wellness lines of products recently purchased by Ameritech.
- Advitech Announces Positive Results of XP-828L Study In Psoriasis
Company reports positive results from its recently completed randomized, multi-center, double-blind, placebo-controlled clinical trial of XP-828L, confirming efficacy and safety.
- Advitech Announces Positive Results of XP-828L Study In Psoriasis
Company reports positive results from its recently completed randomized, multi-center, double-blind, placebo-controlled clinical trial of XP-828L, confirming efficacy and safety.
- Advitech Announces Positive Results of XP-828L Study In Psoriasis
Company reports positive results from its recently completed randomized, multi-center, double-blind, placebo-controlled clinical trial of XP-828L, confirming efficacy and safety.
- Advitech Announces Positive Results of XP-828L Study In Psoriasis
Company reports positive results from its recently completed randomized, multi-center, double-blind, placebo-controlled clinical trial of XP-828L, confirming efficacy and safety.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- Peer-Reviewed Published Study Demonstrates Safety of UC-II®
A recent study published in Toxicology Mechanisms and Methods demonstrates that UC-II®, InterHealth Nutraceuticals’ 40 mg, once-a-day, joint-health ingredient, is safe.
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
BioVittoria Announces the First Customer Beverage To Be Naturally Sweetened With Fruit-Sweetness™ Clorie-Free Fruit Concentrate
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- Jarrow Formulas® YouTube Channel Approaches 1 Million Views as Olympian-Endorsed Product Video Goes Viral
The overwhelming popularity of the 26-second Olympian-endorsed product video, featuring short-track speed skater Katherine Reutter, reaps 1 million views for the Jarrow Formulas® YouTube Channel.
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- ISO14001 certification granted to Indena
Indena has been granted the ISO14001 certification for its main production site of Settala (Milan).
- New Company for “Change-The-World” Entrepreneurs™ Launches
- GMP Labs Expands Liquid Nutraceutical Capabilities
- What Parents Should Know About Kids and Supplements
- What Parents Should Know About Kids and Supplements
- Oats Beat Back Cholesterol
- Oats Beat Back Cholesterol
- Seniors: Pump Up for Strong Bones and Heart
- Seniors: Pump Up for Strong Bones and Heart
|
Omega-3, the fatty acid found in oily fish, could be combined with a commonly used anesthetic to develop drugs to treat breast cancer, according to research published today in the journal Breast Cancer Research. Compounds of Omega-3 fatty acids and propofol reduce the ability of breast cancer cells to develop into malignant tumours, inhibiting cancer cell migration by 50% and significantly reducing their metastatic activity. These new compounds could be developed into a new family of anti-cancer drugs.
Dr Rafat Siddiqui, from the Methodist Research Institute and Indiana University in Indianapolis, and his colleagues studied the effect of two Omega-3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), combined with propofol on a breast cancer cell line in vitro. Omega-3 fatty acids such as DHA and EPA have a minimal effect on cancer cells when applied alone. Propofol is a potent anti-oxidant known to inhibit cancer cell migration by only 5-10%.
The results of the study show that propofol and DHA or EPA have a much more significant effect on cancer cells when used in combination, as conjugates, than when used alone. The conjugates inhibit cancer cell adhesion by 15% and 30% respectively, reduce cell migration by 50% and increase apoptosis by 40%.
"These results suggest that the novel propofol-DHA and propofol-EPA conjugates reported here may be useful for the treatment of breast cancer" conclude Siddiqui and colleagues.
Malignant cancer cells are highly invasive cells that have lost the ability to sense cues from their environment. As a result, they start dividing abnormally, migrate and accumulate into malignant tumours, in a process called metastasis, which is potentially life-threatening. The aim of anti-cancer drugs is therefore to prevent the cells from dividing abnormally and from spreading, to kill the cells, or to cause the cells to kill themselves.
Fatty acids are often attached to drugs, because they facilitate the absorption of the drugs by the cells. Siddiqui and colleagues explain that DHA and EPA might have had this effect on propofol. They add "It is possible that these conjugates provide a mechanism whereby propofol can be retained in cell membranes for a longer duration and therefore enhance its anticancer effects".
Omega-3 fatty acids, like those found in oily fish such as tuna, salmon, herring, sardines and mackerel, are already known to have many positive health benefits. They are commonly recommended for maintaining a healthy heart, as they are known to reduce cholesterol levels and thought to help prevent cardiovascular disease. Research suggests that Omega-3 may also protect against arthritis, lupus, and asthma and help people with biopolar disorder.
###
This press release is based on the article:
Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells Rafat A Siddiqui1, Mustapha Zerouga, Min Wu, Alicia Castillo, Kevin Harvey, Gary P Zaloga and William Stillwell Breast Cancer Research 2005, 7:R645-R654 (7 June 2005) |